Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma.
about
Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer?Protocadherin 17 promoter methylation in tumour tissue from patients with bladder transitional cell carcinomaAberrant methylation of CDH13 is a potential biomarker for predicting the recurrence and progression of non muscle invasive bladder cancer.Clinicopathological significance and potential drug target of T-cadherin in NSCLC.Clinical significance of CDH13 promoter methylation as a biomarker for bladder cancer: a meta-analysisCirculating Biomarkers in Bladder Cancer.Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies.Prognostic significance of CDH13 hypermethylation and mRNA in NSCLC.Epigenetic biomarkers in the blood of patients with urological malignancies.Aberrant methylation of CDH11 predicts a poor outcome for patients with bladder cancer.Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer.Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer.Downregulation of protocadherin-10 expression correlates with malignant behaviour and poor prognosis in human bladder cancer.The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer.Clinical significance of protocadherin-8 (PCDH8) promoter methylation in bladder cancer.Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer.
P2860
Q26744146-1CAA896F-9F63-43D6-8243-99D80278944CQ28307954-5504A649-CBA7-4BB7-A291-92639BDBC517Q34171782-534DC8EF-D602-4A70-BDE1-5D69DEFD7ECCQ34783319-AC810F5D-44C4-4A3C-B7F9-7A911CD0E13BQ36117964-B72FD967-ADE0-45D9-837A-DD129ADAA43CQ37530401-AA5C621B-B8C3-47A8-A1F1-6439B677417BQ38216129-FB1CF7CC-4EAD-4647-BCC1-B1A4E72EC11BQ38266450-DFD2782D-5E53-4207-8FA2-0E27B1A5BE84Q38365422-FE7341D1-CFB3-4155-A348-7DDB84BFD428Q42364210-B763E292-EBCF-4A69-B28F-95F1BEB4F779Q44288628-580A51AB-83BC-4346-9685-EBA3DDC47E24Q44528110-644BD61D-2206-4F4D-9437-3AFA70A3A9EEQ44691945-E00E186F-55D0-463B-BF54-E9A8B988F0AAQ49220712-0D503C34-C7E1-402F-BEB3-2F6411D96646Q54264662-126845F6-6483-47FF-8022-B3F96E3F0F29Q54275602-E2F0F671-F65B-4CA4-A4BE-2E1A1D86E3D0
P2860
Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Clinical significance of CDH13 ...... r transitional cell carcinoma.
@en
Clinical significance of CDH13 ...... r transitional cell carcinoma.
@nl
type
label
Clinical significance of CDH13 ...... r transitional cell carcinoma.
@en
Clinical significance of CDH13 ...... r transitional cell carcinoma.
@nl
prefLabel
Clinical significance of CDH13 ...... r transitional cell carcinoma.
@en
Clinical significance of CDH13 ...... r transitional cell carcinoma.
@nl
P2093
P2860
P1476
Clinical significance of CDH13 ...... r transitional cell carcinoma.
@en
P2093
P2860
P304
P356
10.1177/147323001103900119
P577
2011-01-01T00:00:00Z